Expert Interview
Evaluating Boehringer Ingelheim's Zongertinib and its recent FDA Accelerated Approval in HER2-Mutated NSCLC
Ticker(s): BOEHRINGER INGELHEIMInstitution: South Nassau Oncology
- Senior Partner of South Nassau Oncology, Professor of Medicine at the Mount Sinai Hospital and Former Director of the Cancer Program at the Mount Sinai Hospital
- Manages 25+ NSCLC and 80 patients with AML
- Clinical focus on hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma and leukemias; as well as cancers of the lung, colon and breast.
How do you view the clinical significance of zongertinib’s FDA accelerated approval for patients with HER2 (ERBB2) TKD–mutated NSCLC, particularly compared to existing treatment options?
Added By: sara_adminWhat are the key strengths and limitations you see in the available zongertinib data (efficacy, safety, durability), and how might these influence real-world adoption?
Added By: sara_adminIn your opinion, what factors will determine zongertinib’s uptake in clinical practice, and which patient segments are most likely to benefit from this therapy?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
